In­tra-Cel­lu­lar's check­ered de­vel­op­men­tal path ends in schiz­o­phre­nia ap­proval, shares sky­rock­et

It may be al­most the end of the year, but the FDA’s sta­mi­na for ap­provals has per­se­vered.

On Mon­day, In­tra-Cel­lu­lar Ther­a­pies se­cured the reg­u­la­tor’s bless­ing for its an­tipsy­chot­ic drug, Caply­ta, de­spite two late-stage schiz­o­phre­nia stud­ies that left much to be de­sired. But as is cus­tom with most an­tipsy­chotics, tri­als that fall short typ­i­cal­ly do not nec­es­sar­i­ly de­ter a drug’s path to ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER